Moderna Shares Plunge 26% After Melanoma Vaccine Data Leak

The stock closed down 17.57%. The Phase 3 results showed lower risks of melanoma recurrence or death and distant metastasis or death.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.